The invention provides compositions or pharmaceutical compositions for use in inducing acquired immune lymphocytes to produce type I interferons, inhibiting proliferation of the lymphocytes, and treating diseases or conditions associated with enhanced acquired immunity. Pharmaceutical compositions for use in treating diseases or conditions associated with enhanced acquired immunity, containing a STING ligand compositions for use in inducing T cells to produce type I interferons, containing a STING ligand and proliferation inhibitors of acquired immune lymphocytes containing a STING ligand are provided.
